Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.62 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7993397 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL30234244 | 0.82 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL3088174 | 0.80 | CYP2C9 (0.52) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL10994301 | 0.78 | CYP2C19 (0.50) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL324079 | 0.78 | SLC6A2 (0.50) | CYP1A2CYP2C9CYP2C19FDPSHIF1A | |
| SCHEMBL28607388 | 0.78 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL10476772 | 0.78 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL1421007 | 0.78 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL8208882 | 0.77 | CYP1A2 (0.54) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 | |
| SCHEMBL912792 | 0.77 | CYP2C9 (0.67) | CYP1A2CYP2C9CYP2C19FDPSKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539251-A4 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL CONDITIONS INVOLVING ANGIOGENESIS | GLYCOMIMETICS INC (US) | 2009-02-25 | — | — | EP | disclosed |
| EP-1685145-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GlycoMimetics, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1575619-A1 | OLIGOSACCHARIDES AND CONJUGATES THEREOF FOR THE TREATEMENT OF PSEUDOMONAS BACTERIA INFECTION | Glycomimetics, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | GLYCOMIMETICS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2005054264-A2 | GLYCOMIMETIC ANTAGONISTS FOR BOTH E- AND P-SELECTINS | GLYCOMIMETICS, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1539251-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL CONDITIONS INVOLVING ANGIOGENESIS | Glycomimetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040219158-A1 | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria | GLYCOMIMETICS, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004058304-A1 | OLIGOSACCHARIDES AND CONJUGATES THEREOF FOR THE TREATEMENT OF PSEUDOMONAS BACTERIA INFECTION | GLYCOMIMETICS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040096396-A1 | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis | GLYCOMIMETICS, INC. (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004004636-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF MEDICAL CONDITIONS INVOLVING ANGIOGENESIS | GLYCOMIMETICS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219158-A1 | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria | CFTR, CFB, SERPINB1 | CYP1A2 4259/4885CYP2C9 4441/4885CYP2C19 3509/4885 |
| US-20050187171-A1 | Glycomimetic antagonists for both E-and P-selectins | SELE, SELP, SELPLG | CYP1A2 2452/4885CYP2C9 3423/4885CYP2C19 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.